AACR 101st Annual Meeting 2010: Educational Sessions

Animal Models for Chemoprevention

Chairperson: Stephen S. Hecht, University of Minnesota Masonic Cancer Center, Minneapolis, MN

• Overview of genetically engineered mouse models for chemoprevention
  Cory Abate-Shen, Columbia University Irving Comprehensive Cancer Center, New York, NY
• Animal models for chemoprevention of prostate carcinogenesis
  Tony A-N Kong, Rutgers University College of Pharmacy, Piscataway, NJ
• Animal models for chemoprevention of gastrointestinal tract carcinogenesis
  Gary D. Stoner, The Ohio State University, Columbus, OH
• Animal models for chemoprevention of lung carcinogenesis
  Stephen S. Hecht

Causes of Human Cancer

Chairperson: Vincent Cogliano, International Agency for Research on Cancer (IARC), Lyon, France

• Causes of human cancer, as determined by IARC
  Vincent Cogliano
• Molecular epidemiology and its use in identifying human carcinogens
  Paolo Boffetta, Mount Sinai School of Medicine, New York, NY
• Future research approaches for identifying human carcinogenesis
  Daniel Krewski, University of Ottawa, Ottawa, ON, Canada

Diversity of Stromal Fibroblasts and Their Role in Cancer

Chairperson: Michael C. Ostrowski, The Ohio State University, Columbus, OH

• Stromal diversity in development and cancer progression
  Gerald Cunha, University of California, San Francisco, CA
• Stromal heterogeneity and the paracrine promotion of carcinogenesis
  Simon W. Hayward, Vanderbilt University Medical Center, Nashville, TN
• Defining the role of fibroblasts and pericytes in cancer progression and metastasis
  Raghu Kalluri, Beth Israel Deaconess Medical Center, Boston, MA
• Tumor microenvironment diversity: PTEN and p53 move into the neighborhood
  Gustavo W. Leone, The Ohio State University Comprehensive Cancer Center, Columbus, OH

From Chemistry to the Clinic, Part 1: The Academic/Foundation/Industry Interface

Chairperson: Laurence H. Hurley, University of Arizona, Tucson, AZ

• Drug discovery in academia
  Stephen W. Fesik, Vanderbilt University School of Medicine, Nashville, TN
• Title to be announced
  Louis J. DeGennaro, The Leukemia & Lymphoma Society, White Plains, NY

Imaging the Metastatic Process

Chairperson: Barbara M. Fingleton, Vanderbilt-Ingram Cancer Center, Nashville, TN

• Methods to image cysteine protease activity
  Laura E. Edgington, Stanford University, Stanford, CA
• Imaging metalloproteinase activity
  James Oliver McIntyre, Vanderbilt-Ingram Cancer Center, Nashville, TN
• Methods to image motility
  Patricia J. Keely, University of Wisconsin School of Medicine, Madison, WI
• Imaging the microenvironmental contribution to metastasis
  Mikala Egeblad, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY

New Targets and Novel Drugs for microRNAs and the Epigenetics Machinery

Chairperson: Manel Esteller, Institute d’Investigació Biomèdica de Bellvitge, Barcelona, Spain

• Novel epigenetic and microRNA drugs in cancer therapy
  Manel Esteller
• Recent developments of two NCI epigenetic drugs: Zebularine and 3-deazaneplanocin
  Victor E. Marquez, NCI-Frederick, Frederick, MD
• Sirtuins as therapeutic targets in cancer
  Antonio Bedalov, Fred Hutchinson Cancer Research Center, Seattle, WA
• microRNA processing and target interactions
  John J. Rossi, Beckman Research Institute, Duarte, CA

Nutrition, Obesity, and Cancer

Chairperson: Adriana Albini, IRCCS Multimedica, Milano, Italy

• Obesity, diabetes, and risk of prostate cancer: Results from cancer prevention trials
  Scott M. Lippman, UT M. D. Anderson Cancer Center, Houston, TX
• NF-κB and cancer: Regulation by natural molecules from nutrition
  Bharat B. Aggarwal, UT M. D. Anderson Cancer Center, Houston, TX
• The role of diet and dietary derivatives in chemoprevention and angioprevention
  Adriana Albini
• From soup to nuts: Evaluating bioactive food components in breast cancer prevention trials
  Karen A. Johnson, National Cancer Institute, Bethesda, MD

RANK Ligand (RANKL) Inhibitors for the Treatment of Skeletal Complications of Cancer

Chairperson: William C. Dougall, Amgen, Inc., Seattle, WA

• Introduction: The role of RANKL in the development of cancer-induced bone disease
  Peter Croucher, The Mellanby Centre for Bone Research, Sheffield, United Kingdom
• Strategies for targeting the RANKL/RANK pathway in cancer
  William C. Dougall
• Clinical effects of denosumab on skeletal-related events in cancer patients
  Allan Lipton, Pennsylvania State University, Hershey, PA

Systems and Network Biology of Cancer

Chairperson: Yosef Yarden, Weizmann Institute of Science, Rehovot, Israel

• Oncogenic networks of receptor tyrosine kinases: The example of EGFR and HER2
  Yosef Yarden
• Evolution and selection of alleles in the p53/p63/p73 family of genes: Food, stress, gender, and longevity
  Arnold J. Levine, Institute for Advanced Study, Princeton, NJ
• Genome-targeted therapy for human cancer
  Matthew L. Meyerson, Dana-Farber Cancer Institute, Boston, MA

Tumor Immunology for Non-Immunologists

Chairperson: Olivera J. Finn, University of Pittsburgh School of Medicine, Pittsburgh, PA

• Cancer immunoediting: Immunologic control and shaping of cancer
  Robert D. Schreiber, Washington University School of Medicine, St. Louis, MO
• Tumor antigens and antitumor immunity
  Olivera J. Finn
• Regulation of the immune system by tumor
  Augusto C. Ochoa, Louisiana State University Medical Center, New Orleans, LA
• Cancer immunotherapy
  Martin A. Cheever, Fred Hutchinson Cancer Research Center, Seattle, WA

Angiogenesis: Still Crazy after All These Years

Chairperson: Lee M. Ellis, UT M. D. Anderson Cancer Center, Houston, TX

• Beyond VEGF: Avenues to assess and manipulate the therapeutic window of VEGF/VEGFR therapies
  Hellmut G. Augustin, German Cancer Research Center, Heidelberg, Germany
• Attacking resistance to VEGF-targeted therapy
  Donald M. McDonald, University of California, San Francisco, CA
• Notch ligands as therapeutic targets in tumor angiogenesis
  Jan K. Kitajewski, Columbia University, New York, NY
• VEGF-targeted therapy: Issues and controversies
  Lee M. Ellis

Cancer Stem Cells and Treatment Resistance

Chairperson: Jeremy N. Rich, The Cleveland Clinic, Cleveland, OH

• An evolving concept of cancer stem cells in tumor biology
  Jeremy N. Rich
• Dormancy in normal and malignant stem cells
  Andreas Trumpp, Heidelberg Institute for Stem Cell Technology, Heidelberg, Germany
• Tumorigenic potential is a common attribute of cells in some cancers
  Sean J. Morrison, University of Michigan, Ann Arbor, MI

Cancer Susceptibility Genes and Modifiers

Chairperson: Mary J. C. Hendrix, Children’s Memorial Research Center, Chicago, IL

• Cripto-1: An oncofetal gene involved in stem cell maintenance and malignant progression
  David Salomon, National Cancer Institute, Bethesda, MD
• Tumor metastasis genes control cancer susceptibility
  Marsha R. Rosner, University of Chicago, Chicago, IL
• Lessons learned from investigating breast cancer metastasis susceptibility in mouse models
  Kent W. Hunter, National Cancer Institute, Bethesda, MD
• Telomere length and cancer risk: Cause or consequence, long or short?
  Lifang Hou, Feinberg School of Medicine, Northwestern University, Chicago, IL

Cell Metabolism and Cancer

Chairperson: Reuben J. Shaw, Salk Institute for Biological Studies, La Jolla, CA

• The LKB1/AMPK pathway controls metabolism and cell growth
  Reuben J. Shaw
• Myc coordinates growth and cellular metabolism
  Chi Van Dang, Johns Hopkins University School of Medicine, Baltimore, MD
• Understanding tumor cell metabolism: Lessons from pyruvate kinase
  Matthew G. Vander Heiden, Massachusetts Institute of Technology, Cambridge, MA
• The SDH5 tumor suppressor is a conserved regulator of mitochondrial respiration
  Jared Rutter, University of Utah, Salt Lake City, UT

Chaperones as Therapeutic Targets: Beyond Hsp90

Chairperson: Linda M. Hendershot, St. Jude Children’s Research Hospital, Memphis, TN

• The unique tissue biology of GRP94: Envisioning roles in tumor growth and metastatic dissemination
  Christopher Nicchitta, Duke University Medical Center, Durham, NC
• Targeting the molecular chaperone HSP70 as an anticancer strategy
  Donna L. George, University of Pennsylvania School of Medicine, Philadelphia, PA
• Targeting Hsp27 for treatment of advanced cancer
  Amina Zoubeidi, Vancouver General Hospital, Vancouver, BC, Canada
• The unfolded protein response as a potential therapeutic target for treating cancer
  Linda M. Hendershot

Current Topics in Research for Cancer Prevention

Chairperson: Christine B. Ambrosone, Roswell Park Cancer Institute, Buffalo, NY

• Where are we in understanding cancer risk factors?
  Timothy R. Rebbeck, University of Pennsylvania School of Medicine, Philadelphia, PA
• Promise and pitfalls of chemoprevention trials
  Gary E. Goodman, Fred Hutchinson Cancer Research Center, Seattle, WA
• Role of screening in cancer prevention
  Laura J. Esserman, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

From Chemistry to the Clinic, Part 2: Pharmacokinetics in Cancer Drug Discovery and Development

Chairperson: Andrew P. Krivoshik, Abbott Laboratories, Abbott Park, IL

• Pharmacokinetics in drug discovery
  Michael Michaelides, Abbott Laboratories, Abbott Park, IL
• Pharmacokinetic and pharmacodynamic considerations in translational development
  Andrew P. Krivoshik
• Pharmacokinetics in the clinical development of new anticancer agents: Where the rubber hits the road
  Anthony W. Tolcher, South Texas Accelerated Research Therapeutics, San Antonio, TX
• Regulatory perspective of the role of pharmacokinetics in drug discovery and development
  Brian P. Booth, FDA-CDER, Rockville, MD

microRNAs and Their Binding in Cancer Risk and Development

Chairperson: Joanne B. Weidhaas, Yale University School of Medicine, New Haven, CT

• miRNA polymorphisms and cancer risk
  Joanne B. Weidhaas
• Oncogenic miRNAs in cancer and development
  Andrea Ventura, Memorial Sloan-Kettering Institute, New York, NY
• Functional dissection of a polycistronic miRNA oncogene in lymphomagenesis
  Virginie Olive, University of California, Berkeley, CA
• The other side of posttranscriptional regulation of gene expression in cancer: Altered visibility of transcripts to microRNAs and RNA binding proteins via alternative cleavage and polyadenylation
  Joel R. Neilson, Baylor College of Medicine, Houston, TX

Myeloid-Derived Suppressor Cells (MDSC): A Major Obstacle to Cancer Immunotherapy

Chairperson: Suzanne Ostrand-Rosenberg, University of Maryland Baltimore County, Baltimore, MD

• Tumor-induced immune suppression by myeloid-derived suppressor cells
  Suzanne Ostrand-Rosenberg
• Regulation of myeloid-derived suppressor cells by the tumor microenvironment
  Dmitry I. Gabrilovich, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
• Cross-talk between cancer and bone marrow for the generation of myeloid-derived suppressor cells: The concept of cancer macroenvironment
  Vincenzo Bronte, Istituto Oncologico Veneto, Padova, Italy
• Therapeutic strategies targeting myeloid-derived suppressor cells
  Ivan M. Borello, Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore, MD

Posttranslational Modifications: A Primer

Chairperson: Mary-Ann Bjornsti, University of Alabama, Birmingham, AL

• Unraveling ubiquitin-like modifiers
  Mary-Ann Bjornsti
• Title to be announced
  Linda H. Malkas, Indiana University Cancer Center, Indianapolis, IN
• Deconstructing phosphorylation status regulators
  John S. Lazo, University of Pittsburgh School of Medicine, Pittsburgh, PA
• A sugar coating: Adaptation at the cell surface by protein glycosylation
  James W. Dennis, University of Toronto Mount Sinai Hospital, Toronto, ON, Canada

Site-Specific Metastasis

Chairperson: Patricia S. Steeg, National Cancer Institute, Bethesda, MD

• Mechanisms of site-specific metastasis to bone
  Theresa A. Guise, Indiana University, Indianapolis, IN
• Signaling pathways regulating lung metastasis
  Carrie W. Rinker-Schaeffer, University of Chicago, Chicago, IL
• The tumor microenvironment in different stages of the hepatic metastasis process
  Fernando Vidal-Vanaclocha, CEU-San Pablo University School of Medicine, Madrid, Spain
• Brain metastasis: A unique microenvironment and a sanctuary from chemotherapy
  Patricia S. Steeg

Cancer Microenvironment: Roles of Bone Marrow-Derived Cells

Chairperson: Makoto M. Taketo, Kyoto University Graduate School of Medicine, Kyoto, Japan

• Roles of macrophages in cancer invasion and metastasis
  Jeffrey W. Pollard, Albert Einstein College of Medicine, Bronx, NY
• Roles of bone marrow-derived cells in breast cancer metastasis
  Harold L. Moses, Vanderbilt-Ingram Cancer Center, Nashville, TN
• Roles of bone marrow-derived cells in colon cancer metastasis
  Makoto M. Taketo

Cellular Responses to DNA Damage: Signaling, Repair, and Tolerance

Chairperson: Kristin A. Eckert, Pennsylvania State University College of Medicine, Hershey, PA

• Rad 9, the DNA damage signaling response, and cancer
  Howard B. Lieberman, Columbia University, New York, NY
• Nucleotide excision repair polymorphisms and cancer
  Laura J. Niedernhofer, University of Pittsburgh Cancer Institute, Pittsburgh, PA
• The genetics of base excision repair and cancer risk
  Sheila S. David, University of California, Davis, CA
• DNA polymerase translesion synthesis and damage tolerance
  Kristin A. Eckert

DCIS: An Evolving Case Study for Personalized Medicine

Chairperson: Gary J. Kelloff, National Cancer Institute, Rockville, MD

• Intrinsic subtypes of DCIS
  Charles M. Perou, University of North Carolina, Chapel Hill, NC
• Title to be announced
  D. Craig Allred, Washington University School of Medicine, St. Louis, MO
• Do myoepithelial cells hold the key to DCIS progression?
  Kornelia Polyak, Dana-Farber Cancer Institute, Boston, MA
• PARP inhibitors
  Alex R. Shoemaker, Abbott Laboratories, Abbott Park, IL
• Detection of and drug development for DCIS and precancers
  Gary J. Kelloff

Extracellular Matrix and Cancer: Composition and Architecture

Chairperson: Mary M. Zutter, Vanderbilt University Medical Center, Nashville, TN

• Collagens: They are “mostly” what we are
  Mary M. Zutter
• Signals from the tumor microenvironment: An essential role for ECM glycoproteins
  Jean E. Schwarzbauer, Princeton University, Princeton, NJ
• Proteoglycans: Diversity in structure and function
  Marian Young, National Institute of Dental and Craniofacial Research, Bethesda, MD
• Matricellular proteins as regulators of tumor progression
  Rolf A. Brekken, UT Southwestern Medical Center, Dallas, TX

From Chemistry to the Clinic, Part 3: Chemical Development – Translating a Potent Agent into a Registered Product

Chairperson: Stephen A. Munk, Ash Stevens Inc., Detroit, MI

• On the road from research to reality: Pharmaceutical product development concepts for potent compounds, including AP24534, a novel multitargeted kinase inhibitor
  Christopher K. Murray, ARIAD Pharmaceuticals, Inc., Cambridge, MA
• Discovery and development of the indenoisoquinolines topoisomerase I inhibitors
  Yves G. Pommier, National Institutes of Health, Bethesda, MD
• Pharmaceutical development challenges of the Hsp90 inhibitor IPI-504: A case study in controlling impurity
  Kristopher M. Depew, Infinity Pharmaceuticals, Inc., Cambridge, MA
• The role of the chemical development team in the regulatory approval of a cancer drug
  Vince Ammoscato, Ash Stevens Inc., Detroit, MI

New Perspectives in Pediatric Cancer: From Preclinical Models to Targeted Therapies

Chairperson: Victor M. Santana, St. Jude Children’s Research Hospital, Memphis, TN

• Xenograft models of pediatric acute lymphoblastic leukemia for preclinical evaluation of new drugs
  Richard B. Lock, Children’s Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre at UNSW, Sydney, Australia
• Targeting the IGFIR in pediatric sarcomas: An evolving story
  Lee J. Helman, National Cancer Institute, Bethesda, MD
• Targeted therapy for pediatric gliomas: From bench to bedside
  Angela J. Sievert, Children’s Hospital of Philadelphia, Philadelphia, PA
• Proton beam therapy: Advanced radiation therapy for pediatric malignancies
  Thomas Merchant, St. Jude Children’s Research Hospital, Memphis, TN

Niches for Metastatic Cells and Stem Cells

Chairperson: Amato J. Giaccia, Stanford University School of Medicine, Stanford, CA

• Speakers to be announced

Pharmacogenomics and Personalized Medicine

Chairperson: M. Eileen Dolan, University of Chicago, Chicago, IL

• Tools for discovery of pharmacogenomic markers
  M. Eileen Dolan
• Personalized medicine for breast cancer patients
  Christos Sotiriou, Institut Jules Bordet, Brussels, Belgium
• Personalized medicine for childhood leukemia
  Mary V. Relling, St. Jude Children’s Research Hospital, Memphis, TN
• Towards personalized therapy in ovarian cancer
  Georgia Chenevix-Trench, Queensland Institute of Medical Research, Brisbane, Australia

Transcriptional Coregulators, Chromatin, and Cancer

Chairperson: Rakesh Kumar, George Washington University, Washington, DC

• Nuclear receptor coactivators: Cancer master genes
  Bert W. O’Malley, Baylor College of Medicine, Houston, TX
• Interaction of nuclear receptors with the chromatin landscape
  Gordon L. Hager, National Cancer Institute, Bethesda, MD
• Epigenomics and cistromics of hormone-dependent cancers
  Myles A. Brown, Dana-Farber Cancer Institute, Boston, MA
• Transcriptional coregulators with dual functions in cancer
  Rakesh Kumar

From Chemistry to the Clinic, Part 4: Applications of New Technologies to Drug Discovery

Chairperson: Michael J. Luzzio, Novartis Institutes for BioMedical Research, Cambridge, MA

• Fragment-based discovery: Discovery of TAK-901, a novel multitargeted Aurora-B kinase inhibitor
  Ron de Jong, Takeda San Diego, Inc., San Diego, CA
• Integration of structure-based drug design and physical properties-based optimization to produce cancer
  Martin P. Edwards, Pfizer, Inc., San Diego, CA
• Designing real drugs with the Novartis virtual medicinal chemistry environment (FOCUS)
  Donovan Chin, Novartis Institutes for BioMedical Research, Cambridge, MA

PARP Inhibitors and Synthetic Lethality

Chairperson: A. Hilary Calvert, UCL Cancer Institute, London, United Kingdom

• Development of PARP inhibitors and potential roles in chemo- and radiopotentiation
  A. Hilary Calvert
• DNA repair and synthetic lethality
  Thomas Helleday, Oxford University, Oxford, United Kingdom
• Potential problems: Secondary mutations of BRCA1/2 as a mechanism of drug resistance
  Toshiyasu Taniguchi, Fred Hutchinson Cancer Center, Seattle, WA